TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune, in Patients with Acute Myeloid Leukemia

EDINBURGH, Scotland, Nov. 22, 2022. TC Biopharm (Holdings) PLC ( " TC Biopharm " or the " Company " ), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer today announced the dosing of its first...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials